
    
      This is a multicenter randomized phase II non comparative study. Patients with metastatic NEC
      G3, will be enrolled in the study and will be randomly assigned to receive FOLFIRI or CAPTEM
      as second line treatment The primary objective is to assess DCR and the safety as co-primary
      objective. The secondary objectives are: OS, PFS, quality of life and toxicity of subsequent
      line of therapy (after Progression Disease PD) with an observational purpose.

      The secondary exploratory objectives are the assessment of the impact of PET with gallium on
      PFS and the evaluation of biomarkers

      Study treatment:

      FOLFIRI regimen

        -  Oxaliplatin (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks
           followed by

        -  Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks
           followed by

        -  5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a
           48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of
           12 cycles

      CAPTEM regimen Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with
      temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum
      of 6 cycles.
    
  